Trending Topic

A digital rendering of a human brain with highlighted neural pathways and electric activity, visualizing brain function.
18 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Pavel Burko, Ilias Miltiadis, Mahsa Alavi

Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of both upper and lower motor neurons, which ultimately leads to muscle weakness, atrophy, spasticity and contractures.1 ALS typically manifests in the 50–60 years age range, although familial cases may present in late adolescence or early adulthood.2 The time from the first symptom to diagnosis is approximately 10–16 […]

Georg Ebersbach, MDS 2020 – Opicapone’s Potential as a First-line Adjunctive Therapy for Motor Fluctuations of Parkinson’s Disease

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 23rd 2020

Georg Ebersbach (Movement Disorders Clinic, Beelitz-Heilstaetten, Beelitz, Germany) kindly took the time to talk us through the findings of his presentation entitled: Opicapone’s added benefit as a first-line adjunctive therapy to levodopa and when used promptly in the motor fluctuations spectrum of Parkinson’s disease: a post-hoc analysis of BIPARK-I and II.

ClinicalTrials.gov identifiers for the two large multinational trials included in this post-hoc analysis, that previously demonstrated efficacy and safety of opicapone for end-of-dose motor fluctuations in Parkinson’s disease: NCT01568073 and NCT01227655, respectively.

Questions
1. What impact do motor fluctuations have on patients with Parkinson’s disease (PD)? (0:06)
2. Could you give us a brief overview of the main findings of the BIPARK-I and II studies supporting the use of opicapone in PD? (0:47)
3. What was the rationale for the post-hoc analysis you presented? (1:54)
4. What were the findings of this analysis? (2:24)
5. What are the implications of these findings in terms of the optimum use of opicapone in routine clinical practice? (3:35)

Disclosures: Prof. Ebersbach reports receiving honoraria for lectures and advisory board activities from BIAL, the manufacturer of opicapone.

Support: Interview and filming supported by Touch Medical Media.

Filmed as a highlight of the International Parkinson and Movement Disorder Society MDS Virtual Congress 2020.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup